Regeneron Pharmaceuticals, Inc. (REGN)
REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline?
Regeneron's Q3 earnings on Oct. 28 will likely spotlight Dupixent profits and strong Eylea HD uptake amid lingering Eylea competition.
Earnings Preview: Regeneron (REGN) Q3 Earnings Expected to Decline
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss (Revised)
Regeneron's DB-OTO gene therapy shows hearing gains in nearly all CHORD study participants, with durable and meaningful improvements.
REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss
Regeneron's DB-OTO gene therapy shows hearing gains in nearly all CHORD study participants, with durable and meaningful improvements.
What If You Were Missing The Value In Regeneron Pharmaceuticals Stock?
Here's why we believe Regeneron Pharmaceuticals (REGN) stock merits attention as a value addition. Currently, it is trading almost 44% lower than its 1-year peak and is also priced at a PS multiple below its average from the last 3 years.
Regeneron Gets FDA Nod for Label Expansion of Oncology Drug Libtayo
REGN secures FDA approval to expand Libtayo's label for high-risk skin cancer, boosting its oncology momentum amid Eylea sales pressure.
US FDA expands use of Regeneron's Libtayo as add-on treatment for skin cancer
The U.S. Food and Drug Administration on Wednesday cleared Regeneron Pharmaceuticals' immunotherapy, Libtayo, as an add-on treatment for skin cancer patients at high risk of their disease returning after surgery and radiation, the drugmaker said.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Regeneron Pharmaceuticals catalysts could drive stock higher: analysts
JP Morgan analysts see an “attractive setup” for Regeneron Pharmaceuticals Inc (NASDAQ:REGN) shares, believing the company's Dupixent and Eylea drugs and cash on hand alone support valuation at current levels. In a note to clients on Friday, the analysts wrote that they expect several catalysts for the company over the next three to six months, including Phase 3 trial results for LAG3 melanoma treatment as well as several potential Eylea updates.
Regeneron: Growth Catalysts Incoming
Regeneron Pharmaceuticals, Inc. is rated a Buy, supported by strong Dupixent and oncology growth offsetting Eylea/Eylea HD declines. REGN's robust pipeline, best-in-class products, and upcoming patent expirations position the company well for future revenue and margin expansion. Financials remain solid with significant cash reserves, low debt, and shares trading at an undemanding valuation relative to peers and its own historical measures.
Regeneron: Looking For Green Shoots Of Growth On Top Of Heartwood Franchises
Regeneron Pharmaceuticals remains a top conviction idea, driven by strong Dupixent growth, a robust pipeline, and a healthy balance sheet. REGN's Q2 earnings showed solid revenue and EPS growth, with Dupixent, EYLEA HD, Libtayo, and Lynozyfic all contributing to performance. Despite regulatory delays and competition, the company's pipeline and new indications for key drugs support long-term growth potential.
Regeneron: Drug Pricing Woes Notwithstanding, Due For A Major Comeback
Regeneron Pharmaceuticals, Inc. shares have lost >50% of their value over the past 12 months. Regeneron remains a powerhouse pharma however, despite threats to its key drug Eylea from generics and longer acting therapies. Regeneron also co-markets and sells Dupixent, whose revenues exceeded >$4bn last quarter, with Regeneron earning >$1.4bn.
